Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triferic PK via Hemodialysate vs IV in CKD-5HD
NCT02739100Phase 1Completed
- Sponsor
- Rockwell Medical
- Start
- Apr 2016
- Primary completion
- Jul 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ferric pyrophosphate in anemia of chronic kidney disease (CKD-A) (3 arms), sponsored by Rockwell Medical. Primary endpoints: Maximum Serum Concentration at 12 hours and Area Under the Serum Concentration-time Curve at 12 hours. Started Apr 2016; status: completed.
02
Drugs
ferric pyrophosphate
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT02739100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02739100.